By Mariam Sunny and Bhanvi Satija Jan 28 (Reuters) - U.S. drugmaker Eli Lilly signed an agreement worth up to $1.12 billion ...

Eli Lilly ( LLY 1.52%) is the most valuable healthcare company in the world, with a market cap of around $950 billion. In the ...

By Harshita Mary Varghese and Patrick Wingrove Jan 28 (Reuters) - Novo Nordisk spent nearly $500 million on U.S. advertising ...

Lilly and German biotech Seamless Therapeutics will develop recombinase-based treatments for hearing loss.

Eli Lilly (NYSE: LLY) announced a global research collaboration with Seamless Therapeutics to develop programmable gene ...

Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offering by penning a pact with gene editing ...

Seamless Therapeutics entered into a strategic global research collaboration and licensing agreement with Eli Lilly and ...

Lilly inks gene therapy deal with Seamless Therapeutics to develop programmable recombinase treatments targeting genetic hearing loss worldwide.

The agreement with Seamless is the latest in a series of purchases and partnerships Lilly has established to build a pipeline ...

Eli Lilly is tackling a high-growth market: weight loss. The company’s weight loss portfolio brought in $10 billion in the ...

Both companies may succeed in this industry.

Jan 27 (Reuters) - The U.S. Centers for Medicare & Medicaid Services on Tuesday named a new group of branded drugs from major ...